NCT07096336 Effect of Vitamin D3 on Brain Waves in Male Parkinson's Patients With Low Vitamin D: A qEEG Study
| NCT ID | NCT07096336 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Bangladesh Medical University |
| Condition | PARKINSON DISEASE (Disorder) |
| Study Type | INTERVENTIONAL |
| Enrollment | 15 participants |
| Start Date | 2025-07-15 |
| Primary Completion | 2025-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 15 participants in total. It began in 2025-07-15 with a primary completion date of 2025-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an experimental study (Interventional self-controlled trial, pretest-posttest design). The goal of this clinical trial is to evaluate the effect of vitamin D3 supplementation on quantitative EEG in male Parkinson's disease patients with hypovitaminosis D. The main question it aims to answer is: Vitamin D3 supplementation has effect on brain waves in male Parkinson's disease patients with hypovitaminosis D. Researcher will compare the effect of vitamin D3 supplementation on brain waves in male Parkinson's disease patients with hypovitaminosis D with their pre intervention ( baseline ) condition on brain waves to assess whether there will be any improvement of brain electrical activity by quantitative electroencephalogram (QEEG). Participants will : Take vitamin D3 orally for 8 weeks (50,000 IU/week) Visit the medical university after 8 weeks for evaluation of serum 25(OH)D level and QEEG Must bring the empty strips of vitamin D supplement with them during their visit.
Eligibility Criteria
Inclusion Criteria: * Male Patients with PD up to stage 3 according to Hoehn and Yahr (H-Y) scale * Age: 51years to70 years * BMI: 18.5-24.9 kg/m2 * Hypovitaminosis D (Serum 25(OH)D level \<30 ng/ml) * Patients on Levodopa therapy Exclusion Criteria: * Already taking vitamin D3 supplements * Current use of medication/substances known to affect neuronal excitability or EEG patterns, such as - sedatives, antidepressant, antipsychotics, alcohol. * Patients who are currently suffering from following diseases * Neurological disorders (Migraine, epilepsy) * Cardiovascular disorders (Myocardial infarction, hypertension, cardiac arrhythmia, heart failure) * Respiratory disorders (Bronchial asthma, COPD) * Psychiatric illness (e.g., schizophrenia, major depression, bipolar disorder, severe dementia) * With biochemical evidence of- * Hypercalcemia * Renal insufficiency * Liver diseases * Endocrine disorders (uncontrolled diabetes mellitus, Hypothyroidism, Hyperthyroidism) * Active smoker
Frequently Asked Questions
Who can join the NCT07096336 clinical trial?
This trial is open to male participants only, aged 51 Years or older, up to 70 Years, studying PARKINSON DISEASE (Disorder). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07096336 currently recruiting?
Yes, NCT07096336 is actively recruiting participants. Visit ClinicalTrials.gov or contact Bangladesh Medical University to inquire about joining.
Where is the NCT07096336 trial being conducted?
This trial is being conducted at Dhaka, Bangladesh.
Who is sponsoring the NCT07096336 clinical trial?
NCT07096336 is sponsored by Bangladesh Medical University. The trial plans to enroll 15 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.